IMRX Key Statistics, Chart & Performance
The current stock price of IMRX is 5.5414 USD. In the past month the price decreased by -17.05%. In the past year, price increased by 187%.
IMRX Latest News, Press Relases and Analysis
IMRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.91 | 399.34B | ||
| AMGN | AMGEN INC | 15.08 | 177.62B | ||
| GILD | GILEAD SCIENCES INC | 14.69 | 149.24B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.07 | 114.81B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.58 | 78.45B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 770.87 | 51.94B | ||
| INSM | INSMED INC | N/A | 43.12B | ||
| NTRA | NATERA INC | N/A | 31.14B | ||
| BIIB | BIOGEN INC | 10.29 | 25.28B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.95 | 21.54B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.33B | ||
| INCY | INCYTE CORP | 15.31 | 19.29B |
Related stock screener links
About IMRX
Company Profile
Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. The company is headquartered in Cambridge, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2021-07-30. The firm is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
Company Info
IMMUNEERING CORP - CLASS A
245 Main Street, Second Floor
Cambridge MASSACHUSETTS US
CEO: Benjamin J. Zeskind
Employees: 54
Phone: 16175008080
IMMUNEERING CORP - CLASS A / IMRX FAQ
What does IMMUNEERING CORP - CLASS A do?
Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. The company is headquartered in Cambridge, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2021-07-30. The firm is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
Can you provide the latest stock price for IMMUNEERING CORP - CLASS A?
The current stock price of IMRX is 5.5414 USD. The price decreased by -3.46% in the last trading session.
Does IMMUNEERING CORP - CLASS A pay dividends?
IMRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of IMRX stock?
IMRX has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is IMRX stock listed?
IMRX stock is listed on the Nasdaq exchange.
What is the outstanding short interest for IMMUNEERING CORP - CLASS A?
The outstanding short interest for IMMUNEERING CORP - CLASS A (IMRX) is 13.75% of its float.
IMRX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to IMRX. When comparing the yearly performance of all stocks, IMRX is one of the better performing stocks in the market, outperforming 95.56% of all stocks.
IMRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IMRX. IMRX has a great financial health rating, but its profitability evaluates not so good.
IMRX Financial Highlights
Over the last trailing twelve months IMRX reported a non-GAAP Earnings per Share(EPS) of -1.78. The EPS increased by 9.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -155.1% | ||
| ROE | -214.71% | ||
| Debt/Equity | 0 |
IMRX Forecast & Estimates
12 analysts have analysed IMRX and the average price target is 17.17 USD. This implies a price increase of 209.85% is expected in the next year compared to the current price of 5.5414.